Skip to main content
ANAPTYSBIO, INC logo

ANAPTYSBIO, INC — Investor Relations & Filings

Ticker · ANAB ISIN · US0327241065 LEI · 529900HH4WQT03IG1A12 US Professional, scientific and technical activities
Open in API
Filings indexed 636 across all filing types
Latest filing 2026-05-29 Regulatory Filings
Country US United States of America
Listing US ANAB

About ANAPTYSBIO, INC

https://www.anaptysbio.com/

AnaptysBio, Inc. is a clinical-stage biotechnology company that focuses on the discovery and development of innovative immunology therapeutics. The company specializes in advancing immune cell-modulating antibodies designed to treat autoimmune and inflammatory diseases. Its therapeutic candidates target key pathways in the immune system to address significant unmet medical needs for various patient populations.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 80% confidence The document is a Form 8-K “Current Report” filed under Regulation FD (Item 7.01) disclosing the filing of Form 8937 and providing tax information on a spin-off dividend. It does not contain financial statements or actual dividend amounts/dates but instead is a routine SEC compliance filing. This falls under general regulatory filings (RNS).
2026-05-29 English
8-K
Regulatory Filings Classification · 87% confidence The document is a U.S. SEC Form 8-K "Current Report" announcing Item 5.03 (Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year). It does not contain substantive financial statements or fall into categories like earnings, director changes, M&A, financing, dividends, or governance guidelines presentations. This is a regulatory compliance event notice, making the generic Regulatory Filings (RNS) category the appropriate classification.
2026-05-21 English
8-K - ANAPTYSBIO, INC (0001370053) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated April 20, 2026, reporting a significant corporate event: the completion of a spin-off of First Tracks Biotherapeutics, Inc. from AnaptysBio, Inc. The text includes detailed descriptions of the Separation and Distribution Agreement and Transition Services Agreement related to the spin-off, outlining asset and liability allocations between the two entities. Form 8-K filings are current reports used to announce major events that shareholders should know about, such as spin-offs, material definitive agreements, or other significant corporate changes. This document is not a full annual or quarterly report, audit report, earnings release, or other detailed financial report. It is a regulatory filing announcing a material event. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (15,000 characters) and detailed content confirm it is not a brief announcement but a substantive regulatory filing. Confidence is high due to the clear identification of the form type and content.
2026-04-20 English
4 - ANAPTYSBIO, INC (0001370053) (Issuer)
Director's Dealing
2026-03-28 English
8-K - ANAPTYSBIO, INC (0001370053) (Filer)
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes announcements of a spin-off distribution, a private placement financing, termination of a sales agreement, appointment of a new director, executive officer transitions, and a stock buyback program authorization. These are all discrete corporate events and updates rather than a full financial report or earnings release. The document is lengthy (15,000 characters) and contains detailed descriptions of agreements and corporate governance changes. The primary focus is on material definitive agreements, management changes, and capital raising activities. Therefore, the classification best fitting this document is Capital/Financing Update (CAP) due to the private placement and stock repurchase plan announcements, combined with Board/Management Information (MANG) for the director appointment and executive transitions. However, since the document is a single Form 8-K covering multiple items, the dominant theme is the capital raising and spin-off financing event. Hence, the most appropriate single classification is Capital/Financing Update (CAP).
2026-03-27 English
SCHEDULE 13G/A - ANAPTYSBIO, INC (0001370053) (Subject)
Major Shareholding Notification
2026-03-26 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.